Norges Bank
VKTX icon

Norges Bank’s Viking Therapeutics VKTX Stock Holding History

Norges Bank’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,767,777
Closed -$46.8M – 1516
2025
Q2 		$46.8M Buy
1,767,777
+222,245
+14% +$5.85M 0.01% 979
2025
Q1 		$37.3M Buy
1,545,532
+266,604
+21% +$8.43M 0.01% 1048
2024
Q4 		$51.5M Buy
1,278,928
+8,587
+0.7% +$490K 0.01% 951
2024
Q3 		$80.4M Buy
1,270,341
+1,087,972
+597% +$63.8M 0.01% 767
2024
Q2 		$9.67M Buy
182,369
+100,670
+123% +$6.6M ﹤0.01% 1405
2024
Q1 		$6.7M Buy
+81,699
New +$3.64M ﹤0.01% 1562
2023
Q3 		– Sell
-271,000
Closed -$4.39M – 2035
2023
Q2 		$4.39M Buy
+271,000
New +$5.68M ﹤0.01% 1750

Other funds holding VKTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Norges Bank's VKTX Position: Q3 2025 in Review

Norges Bank sold out of Viking Therapeutics (VKTX) in Q3 2025, closing a stake of 1,767,777 shares — an estimated $46.8M sold.

Norges Bank first reported a position in VKTX in Q2 2023 and held it in 7 quarters. The position peaked at $80.4M in Q3 2024. 370 funds tracked by Wall St. Rank hold VKTX as of Q3 2025.

  • Norges Bank reported no remaining Viking Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Norges Bank sold 1,767,777 Viking Therapeutics shares in Q3 2025, an estimated $46.8M.
  • Norges Bank first reported a position in Viking Therapeutics in Q2 2023 and held it in 7 quarters.
  • Norges Bank's Viking Therapeutics position peaked at $80.4M in Q3 2024.
  • 370 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2025.

Based on Norges Bank's 13F filing for Q3 2025.